Fu Hong Hanlin: The first patient has been dosed in the bridging trial of the first-line treatment of ES-SCLC with the combination therapy of Hans.

ES-SCLC3202112 Fuhong Hanlin announced that the first patient dosing for the bridging study of the company's independently developed Hanshizhuang combined chemotherapy for first-line treatment of extensive-stage small cell lung cancer in Japan has been completed. The purpose of this trial is to support the application for market approval of Hanshizhuang in Japan. Previously, an international, multi-center Phase 3 clinical trial comparing Hanshizhuang or placebo combined chemotherapy for first-line treatment of ES-SCLC reached the primary endpoint of overall survival in December 2021.